Pfizer (PFE) Saturday reported that its Phase 3 BASIS study demonstrated HYMPAVZI (marstacimab) significantly improved bleeding outcomes in adults and adolescents with hemophilia A or B with inhibitors, compared with on-demand bypassing agents.
The therapy is administered as a simple once-weekly injection with minimal preparation and no lab monitoring.
The findings were shared in an oral presentation at the 67th American Society of Hematology Annual Meeting and Exposition in Orlando and published in Blood.
Pfizer (PFE) has submitted these data to the U.S. Food and Drug Administration and European Medicines Agency for review.
HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors.
